Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001079973-25-000265
Filing Date
2025-02-14
Accepted
2025-02-14 16:43:20
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6405
  Complete submission text file 0001079973-25-000265.txt   8562
Mailing Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301
Business Address 333 LAS OLAS WAY CU4 SUITE 433 FORT LAUDERDALE FL 33301 954-515-0810
Sunshine Biopharma Inc. (Subject) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-85054 | Film No.: 25630118
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001
Business Address 161A SHEDDEN ROAD ONE ARTILLERY COURT P.O. BOX 10085 GRAND CAYMAN E9 KY1-1001 646-688-5654
L1 Capital Global Opportunities Master Fund, Ltd. (Filed by) CIK: 0001702202 (see all company filings)

EIN.: 981241877 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A